These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8090694)

  • 1. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts.
    Rump AF; Acar D; Rösen R; Klaus W
    Pharmacol Toxicol; 1994; 74(4-5):244-8. PubMed ID: 8090694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts.
    Rump AF; Acar D; Klaus W
    Br J Pharmacol; 1994 Jul; 112(3):757-62. PubMed ID: 7921599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ca2+ sensitizer superior to catecholamine during myocardial stunning?
    Meyer K; Klocke RC; Schipke JD; Gams E; Korbmacher B
    Eur J Cardiothorac Surg; 2008 Aug; 34(2):326-31. PubMed ID: 18539040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan in regional myocardial ischemia.
    Pieske B
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):379-81. PubMed ID: 12656119
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of amrinone and milrinone on myocardial ischemia extent and infarct size in isolated rabbit hearts.
    Rump AF; Blazincic B; Klaus W
    Arzneimittelforschung; 1993 Dec; 43(12):1262-6. PubMed ID: 8141811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.
    Harkin CP; Pagel PS; Tessmer JP; Warltier DC
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):179-88. PubMed ID: 7475041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?
    Zimmermann N; Boknik P; Gams E; Herzig JW; Neumann J; Scholz H
    Eur J Cardiothorac Surg; 1998 Jul; 14(1):70-5. PubMed ID: 9726618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotropic, vasodilating and preconditioning actions of levosimendan in the heart.
    Meyer K; Schipke JD; Klocke RC; Gams E; Korbmacher B
    Thorac Cardiovasc Surg; 2008 Oct; 56(7):379-85. PubMed ID: 18810693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Milrinone and levosimendan during porcine myocardial ischemia -- no effects on calcium overload and metabolism.
    Axelsson B; Johansson G; Abrahamsson P; Gupta A; Tydén H; Wouters P; Haney M
    Acta Anaesthesiol Scand; 2013 Jul; 57(6):719-28. PubMed ID: 23517167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan.
    Haikala H; Kaheinen P; Levijoki J; Lindén IB
    Cardiovasc Res; 1997 Jun; 34(3):536-46. PubMed ID: 9231037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of levosimendan on the left ventricular function and protein phosphorylation in post-ischemic guinea pig hearts.
    Kristof E; Szigeti G; Papp Z; Bodi A; Ball NA; Walsh RA; Edes I
    Basic Res Cardiol; 1999 Aug; 94(4):223-30. PubMed ID: 10505421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
    Udvary E; Papp JG; Végh A
    Br J Pharmacol; 1995 Feb; 114(3):656-61. PubMed ID: 7735692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan, a new inotropic and vasodilator agent.
    Toller WG; Stranz C
    Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of programmed forms of cell death by intracoronary levosimendan during regional myocardial ischemia in anesthetized pigs.
    Grossini E; Caimmi PP; Platini F; Molinari C; Uberti F; Cattaneo M; Valente G; Mary DA; Vacca G; Tessitore L
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):5-15. PubMed ID: 20162343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.
    Pagel PS; Harkin CP; Hettrick DA; Warltier DC
    Anesthesiology; 1994 Oct; 81(4):974-87. PubMed ID: 7943849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart.
    Edes I; Kiss E; Kitada Y; Powers FM; Papp JG; Kranias EG; Solaro RJ
    Circ Res; 1995 Jul; 77(1):107-13. PubMed ID: 7788868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
    Biala A; Martonen E; Kaheinen P; Levijoki J; Finckenberg P; Merasto S; Louhelainen M; Muller DN; Luft FC; Mervaala E
    Hypertens Res; 2010 Oct; 33(10):1004-11. PubMed ID: 20811386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of levosimendan on myocardial infarct size and hemodynamics in a closed-chest porcine ischemia-reperfusion model.
    Busk M; Maeng M; Kristensen J; Berg JS; Mortensen UM; Nielsen TT; Nielsen-Kudsk JE
    Cardiovasc Drugs Ther; 2006 Oct; 20(5):335-42. PubMed ID: 17122904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.